<DOC>
	<DOCNO>NCT01963208</DOCNO>
	<brief_summary>The study evaluate effectiveness safety investigational drug-ganaxolone - partial seizure frequency adult epilepsy take maximum 3 antiepileptic medication ( AEDs ) .</brief_summary>
	<brief_title>Phase 3 Study Adjunctive Ganaxolone Adults With Drug-resistant Partial Onset Seizures Open-label Extension</brief_title>
	<detailed_description>This 2-cohort study comprise 2 phase cohort . Phase 1 double-blind phase follow Phase 2 , open-label phase . Cohort 1 provide tolerability , safety , PK information ganaxolone 1200mg/d , 1800mg/d placebo . Cohort 2 investigate efficacy , tolerability safety ganaxolone 1800mg/d compare placebo . Cohort 1 ( N= approximately 50 ) enroll 67-week study comprise 4-week prospective baseline period plus 4 week retrospective baseline follow two treatment phase : 9-week randomized DB placebo-controlled treatment phase follow 52-week open label ( OL ) treatment phase . Cohort 2 ( N=150 ) enroll 72-week study comprise 8-week prospective baseline period follow two treatment phase : 14-week randomized DB placebo-controlled treatment phase follow 52-week open label ( OL ) treatment phase .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Pregnanolone</mesh_term>
	<criteria>Able give inform consent writing , legally authorize representative able Willing enter participate full term double blind phase willing enter openlabel phase Male female outpatient &gt; 18 year age Have confident diagnosis drugresistant epilepsy partialonset seizure ( POS ) , without secondary generalization , â‰¥2 year . Have residual POS despite treat past least 2 approve antiepilepsy drug ( AEDs ) either alone combination Based history , subject would anticipate least 3 POS 4week Baseline period unlikely 21 consecutive POSfree day Currently treat maintain stable regimen 1 , 2 , 3 AEDs Able willing maintain daily seizure calendar Able willing take drug food twice daily Sexually active woman childbearing potential must use acceptable birth control negative pregnancy test visit Have previous exposure ganaxolone Known sensitivity allergy component study drug , progesterone , relate steroid compound Exposure investigational drug device &lt; 30 day prior screen , plan take another investigational drug time study Time onset epilepsy treatment &lt; 2 year prior enrollment Have generalize epilepsy , LennoxGastaut syndrome , juvenile myoclonic epilepsy , absence epilepsy , nonepileptic seizure within last 12 month period prior study entry Have le 3 POS seizure 28day period 21 consecutive seizurefree day Baseline period Have simple partial seizure without observable motor component Have innumerable seizure status epilepticus within last 12months prior screen Have 100 POS per 4week Baseline period Have seizure secondary illicit drug alcohol use , infection , neoplasm , demyelinate disease , degenerative neurological disease , central nervous system ( CNS ) disease deem progressive , metabolic illness , progressive degenerative disease Current use vigabatrin permit . If prior use vigabatrin , must document stable visual field Current use ezogabine permit . If prior use , must medication least 3 month prior screen document normal fundoscopic exam ophthalmologist Are plan surgery , evaluate surgery , double blind phase control seizures include VNS implantation Are suffer acute progressive neurological disease , moderate severe psychiatric disease , severe mental abnormality likely require change drug therapy double blind portion study interfere objective study ability adhere protocol requirement Have history actual suicide attempt last 5 year 1 lifetime suicide attempt Have positive urine drug screen Screening meet criterion current historical Substance Use Disorder ( DSMV criterion ) within past 5 year . Have medical condition , investigator 's judgment , consider clinically significant could potentially affect subject safety study outcome , include limited : clinically significant cardiac , renal , pulmonary , gastrointestinal , hematologic hepatic condition ; condition affect absorption , distribution , metabolism excretion drug Have elevate ALT ( SGPT ) AST ( SGOT ) great 3 time upper limit normal , total bilirubin great 1.5 time ULN Have history malignancy within past 2 year , exception basal cell carcinoma Are currently follow plan follow ketogenic diet Use dietary supplement herbal preparation permit subject use consistently less 6 month prior screen , plan remain stable dos duration double blind phase . Use St. John 's Wort permit Females pregnant , currently breastfeed plan become pregnant duration study A history chronic noncompliance drug regimens Inability withhold grapefruit grapefruit juice diet entire clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>partial onset seizure</keyword>
	<keyword>complex partial seizure</keyword>
	<keyword>simple partial seizure</keyword>
	<keyword>anticonvulsant</keyword>
	<keyword>ganaxolone</keyword>
	<keyword>neurosteroid</keyword>
	<keyword>Marinus</keyword>
	<keyword>epilepsy</keyword>
</DOC>